Future Research With CAR T in Lymphoma: Julie Vose, MD

Video

The professor and chief, of oncology and hematology at University of Nebraska Medical Center discussed research with CAR T therapy in lymphoma.

This content originally appeared on our sister site, OncLive.

OncLive spoke with Julie M. Vose, MD, MBA, Neumann M. and Mildred E. Harris Professor, chief, Division of Oncology and Hematology, Department of Internal Medicine, University of Nebraska Medical Center, about future research efforts with CAR T-cell therapy in lymphoma.

CAR T-cell therapies are being evaluated in ongoing clinical trials for patients with lymphoma as well as other indications. Vose discussed how some studies are investigating different designs of CAR T-cell therapies, utilizing CAR T-cell therapy in various subtypes of lymphoma, and potentially incorporating the cellular therapy into earlier lines of treatment. These efforts may yield opportunities to decrease CAR T-cell therapy­–related toxicities for patients, Vose explains.

Additionally, research efforts are evaluating whether combination regimens with CAR T-cell therapies and other agents, such as BTK inhibitors, are feasible for patients with lymphoma, Vose says. It may also be possible to utilize pre- and post-CAR T-cell therapy radiation to try to enhance efficacy, Vose continues. Additionally, evaluating different types of monoclonalantibodies, bispecific antibodies, or other new agents alone or in combination with CAR T-cell therapy could lend future treatment options for patients, Vose concludes.

Newsletter

Stay at the forefront of cutting-edge science with CGT—your direct line to expert insights, breakthrough data, and real-time coverage of the latest advancements in cell and gene therapy.

Recent Videos
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira, and Kilian Guse, PhD, the vice president of genetic medicine platforms at Pacira
Derek Jackson, BS, MA, the vice president of cell & gene therapy product development at Pacira
Jeffrey Chamberlain, PhD
Tami John, MD
Tami John, MD
Tami John, MD
Matthew Ku, MBBS, FRACP, RACP, FRCPA/RCPA, PhD, an associate professor and the lymphoma stream lead at St Vincent’s Hospital
Saurabh Dahiya, MD, FACP, an associate professor of medicine at Stanford University School of Medicine; as well as clinical director of Cancer Cell Therapy in the Division of Blood and Marrow Transplantation and Cell Therapy at Stanford Medicine
Shahzad Raza, MD, a hematologist/oncologist at the Cleveland Clinic
Manali Kamdar, MD, the associate professor of medicine–hematology and clinical director of lymphoma services at the University of Colorado
Related Content
© 2025 MJH Life Sciences

All rights reserved.